ADHERENCE: A REAL WORLD RETROSPECTIVE DATABASE STUDY AMONG TYPE 2 DIABETES PATIENTS TREATED WITH LIRAGLUTIDE OR EXENATIDE

被引：0
|
作者：
Maria, M. [1 ]
Carlqvist, P. [2 ]
Langer, J. [3 ]
Bouchard, J. [3 ]
机构：
[1] Evidence Dev Ltd, Stockholm, Sockholm, Sweden
[2] Heron AB, Stockholm, Sweden
[3] Novo Nordisk Inc, Princeton, NJ USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1695
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A503 / A503
页数：1
相关论文
共 50 条
  • [21] A Retrospective Database Study of Liraglutide Persistence Associated with Glycemic and Body Weight Control in Patients with Type 2 Diabetes
    Melzer-Cohen, Cheli
    Chodick, Gabriel
    Husemoen, Lise Lotte N.
    Rhee, Nicolai
    Shalev, Varda
    Karasik, Avraham
    DIABETES THERAPY, 2019, 10 (02) : 683 - 696
  • [22] MEDICATION ADHERENCE AND MEDICAL COSTS ASSOCIATED WITH EXENATIDE BID VERSUS LIRAGLUTIDE: A RETROSPECTIVE DATABASE ANALYSIS
    Pelletier, E. M.
    Pawaskar, M.
    Chapman, R.
    VALUE IN HEALTH, 2012, 15 (04) : A179 - A180
  • [23] Metformin adherence and discontinuation among patients with type 2 diabetes: A retrospective cohort study
    Tang, Yuexin
    Weiss, Tracey
    Liu, Jinan
    Rajpathak, Swapnil
    Khunti, Kamlesh
    JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY, 2020, 20
  • [24] REAL-WORLD COMPARISON OF HEALTHCARE COSTS AMONG PATIENTS WITH TYPE 2 DIABETES TREATED WITH DULAGLUTIDE VS. LIRAGLUTIDE IN THE UNITED STATES
    Mody, R.
    Huang, Q.
    Yu, M.
    Patel, H.
    Zhao, R.
    Grabner, M.
    Lando, Fernandez L.
    VALUE IN HEALTH, 2018, 21 : S80 - S80
  • [25] HEMOGLOBIN A1C (A1C) REDUCTION AND DIABETES-RELATED HEALTH CARE COSTS AMONG TYPE 2 DIABETES (T2DM) PATIENTS TREATED WITH LIRAGLUTIDE OR EXENATIDE: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS
    Mocarski, M.
    Tian, Y.
    Buysman, E. K.
    Wolbeck, R.
    VALUE IN HEALTH, 2016, 19 (07) : A666 - A666
  • [26] Study of Postprandial Lipaemia in Type 2 Diabetes Mellitus: Exenatide versus Liraglutide
    Voukali, Maria
    Kastrinelli, Irene
    Stragalinou, Sapfo
    Tasiopoulou, Dimitra
    Paraskevopoulou, Pinelopi
    Katsilambros, Nicholas
    Kokkinos, Alexandros
    Tentolouris, Nicholas
    Ioannidis, Ioannis
    JOURNAL OF DIABETES RESEARCH, 2014, 2014
  • [27] REAL WORLD OUTCOMES IN TYPE 2 DIABETES: LOWER COST OF TREATING PATIENTS TO A1C<7% WITH LIRAGLUTIDE VERSUS EXENATIDE
    Dekoven, M.
    Lee, W. C.
    Bouchard, J. R.
    Massoudi, M.
    Langer, J.
    VALUE IN HEALTH, 2013, 16 (07) : A438 - A438
  • [28] Interindividual differences in the clinical effectiveness of liraglutide in Type 2 diabetes: a real-world retrospective study conducted in Spain
    Gomez-Peralta, F.
    Lecube, A.
    Fernandez-Marino, A.
    Alonso Troncoso, I.
    Morales, C.
    Morales-Perez, F. M.
    Guler, I.
    Cadarso-Suarez, C.
    DIABETIC MEDICINE, 2018, 35 (11) : 1605 - 1612
  • [29] Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy
    Maureen J. Lage
    Rosalind Fabunmi
    Kristina S. Boye
    Derek A. Misurski
    Advances in Therapy, 2009, 26 : 217 - 229
  • [30] Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy
    Lage, Maureen J.
    Fabunmi, Rosalind
    Boye, Kristina S.
    Misurski, Derek A.
    ADVANCES IN THERAPY, 2009, 26 (02) : 217 - 229
12345